Publications by authors named "Gunavanthi Boorgula"

Claim this Profile
E
Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of lung disease.
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, Mary C Long, Brian Robbins

Microbiol Spectr· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol in lung disease.
Tawanda Gumbo, Gunavanthi D Boorgula, Shashikant Srivastava

Antimicrob Agents Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease.
Sanjay Singh, Gunavanthi D Boorgula, Minh-Vu H Nguyen, Charles L Daley, Tawanda Gumbo

J Antimicrob Chemother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against .
Avneesh Shrivastava, Gunavanthi D Boorgula, Sanjay Singh, Danaleigh Stiles, Pamela J McShane

Microbiol Spectr· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for Lung Disease.
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, Mary C Long, Brian Robbins

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease.
Sanjay Singh, Tawanda Gumbo, Jann-Yuan Wang, Gunavanthi D Boorgula, Andrew Burke

J Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivacaftor affects the susceptibility of standard-of-care drugs used to treat lung disease.
Avneesh Shrivastava, Sanjay Singh, Gunavanthi D Boorgula, Rodolfo-Amaro Galvez, Shashikant Srivastava

Antimicrob Agents Chemother· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mechanistic understanding of the effect of VraS histidine kinase single-point mutation on antibiotic resistance.
Liaqat Ali, Salima Karki, Gunavanthi D Boorgula, Amir Mekakda, Brittnee Cagle-White

Microbiol Spectr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.
Vanessa B Vogensen, Sanjay Singh, Christopher J Allende, David M Engelthaler, Gunavanthi D Boorgula

Antimicrob Agents Chemother· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mechanistic understanding of the effect of VraS histidine kinase single point mutation on antibiotic resistance.
Liaqat Ali, Salima Karki, Gunavanthi D Boorgula, Amir Mekakda, Brittnee Cagle-White

bioRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients.
Devyani Deshpande, Gesham Magombedze, Gunavanthi D Boorgula, Moti Chapagain, Shashikant Srivastava

J Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.
Gunavanthi D Boorgula, Tawanda Gumbo, Sanjay Singh, Pamela J McShane, Julie V Philley

Tuberculosis (Edinb)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant in the hollow fiber system model.
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley

Antimicrob Agents Chemother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far.
Sanjay Singh, Gunavanthi D Boorgula, Santosh Aryal, Julie V Philley, Tawanda Gumbo

J Antimicrob Chemother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
Sanjay Singh, Tawanda Gumbo, Jan-Willem Alffenaar, Gunavanthi D Boorgula, Prem Shankar

Int J Antimicrob Agents· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.
Sanjay Singh, Jann-Yuan Wang, Scott K Heysell, Pamela J McShane, Carly Wadle, Gunavanthi D Boorgula

Int J Antimicrob Agents· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii.
Gunavanthi D Boorgula, Sanjay Singh, Prem Shankar, Tawanda Gumbo, Scott K Heysell

Tuberculosis (Edinb)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria.
Prem Shankar, Sanjay Singh, Gunavanthi D Boorgula, Tawanda Gumbo, Scott K Heysell

Tuberculosis (Edinb)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Prem Shankar, Scott K Heysell

Antimicrob Agents Chemother· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tick Intrastadial Feeding and Its Role on IgE Production in the Murine Model of Alpha-gal Syndrome: The Tick "Transmission" Hypothesis.
L Paulina Maldonado-Ruiz, Gunavanthi D Boorgula, Donghun Kim, Sherry D Fleming, Yoonseong Park

Front Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
Shashikant Srivastava, Gunavanthi D Boorgula, Jann-Yuan Wang, Hung-Ling Huang, Dave Howe

Antimicrob Agents Chemother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
Shashikant Srivastava, Jotam G Pasipanodya, Scott K Heysell, Gunavanthi D Boorgula, Tawanda Gumbo

J Glob Antimicrob Resist· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected winter questing activity of ticks in the Central Midwestern United States.
Ram K Raghavan, Zoe L Koestel, Gunavanthi Boorgula, Ali Hroobi, Roman Ganta

PLoS One· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diversity and seasonality of host-seeking ticks in a periurban environment in the Central Midwest (USA).
Ali Hroobi, Gunavanthi D Boorgula, David Gordon, Jianfa Bai, Doug Goodin

PLoS One· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Rifamycins for Efficacy Against Complex and Resistance Emergence in the Hollow Fiber Model System.
Gunavanthi D Boorgula, Laxmi U M R Jakkula, Tawanda Gumbo, Bockgie Jung, Shashikant Srivastava

Front Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis